otq923
novartis
['otq923', 'plerixa', 'crispr']
 this product has guiderna for cas9 cutting at these two sites -- indels at the hgb1 +/- hgb2. found 80-85% indel deletion in preclinical validations. eligibility for the study here. #ash22 2/n 
Peds hem/onc enthusiast with interest in med ed (and now a PD @ UCSF), QI & safety, hemostasis/thrombosis. Former Saipan pediatrician. Tweets are my own